Sermorelin & GHRP-6 & GHRP-2 Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Confirmed high-severity market-integrity event (enforcement / recall / counterfeit) · No verifiable third-party COA path in this market

Transparent blend · bci-1.0 · never paid-placement

Primary name

Sermorelin & GHRP-6 & GHRP-2 Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic GHRH(1-29) fragment that stimulates pulsatile GH release via pituitary GHRHR; formerly FDA-approved as Geref (discontinued 2008). Research use only.

Sermorelin acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a Gs-protein-coupled receptor expressed on anterior pituitary somatotroph cells. Binding stimulates adenylyl cyclase, increases intracellular cyclic AMP, activates protein kinase A, and promotes both synthesis and pulsatile exocytotic release of endogenous growth hormone. Because sermorelin acts upstream of the pituitary — causing the gland to release its own GH rather than supplying exogenous hormone — the resulting GH profile mirrors physiological pulsatility and remains subject to normal negative-feedback inhibition by somatostatin, which limits the degree of GH elevation achievable. Downstream GH signalling drives hepatic IGF-1 synthesis and the anabolic, lipolytic, and growth-promoting effects associated with the GH/IGF-1 axis.

Molar mass

3357.9 g/mol

Synthetic hexapeptide GHS-R1a agonist that triggers pulsatile GH release from pituitary somatotrophs; widely used in preclinical secretagogue research.

GHRP-6 is a selective agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor activated by the endogenous orexigenic hormone ghrelin. Binding to GHS-R1a on pituitary somatotrophs couples through Gq/11 proteins to activate phospholipase C, generating IP3 and diacylglycerol, which mobilizes intracellular calcium stores and triggers exocytotic release of stored GH. Concurrently, GHRP-6 acts at hypothalamic GHS-R1a to suppress somatostatinergic tone and stimulate endogenous GHRH release, amplifying pituitary GH output through a dual central-pituitary mechanism. Secondary receptor interactions also lead to modest stimulation of cortisol and prolactin secretion, and prominent appetite stimulation via central ghrelin mimicry — effects that distinguish GHRP-6 from more selective secretagogues such as ipamorelin.

Molar mass

873.0 g/mol

Synthetic hexapeptide GHS-R1a agonist (pralmorelin) that stimulates pulsatile GH release; approved in Japan as a GH-deficiency diagnostic agent.

GHRP-2 binds and activates GHS-R1a, a Gq/11-coupled receptor expressed on pituitary somatotrophs and hypothalamic arcuate neurons. Receptor engagement triggers phospholipase C activation, inositol trisphosphate-mediated intracellular calcium mobilisation, and exocytosis of stored GH. Simultaneously, GHRP-2 potentiates the endogenous GHRH signal in the hypothalamus and partially suppresses somatostatin tone, producing a synergistic amplification of the pulsatile GH release that exceeds either pathway alone. Cortisol and prolactin secretion are also modestly elevated, reflecting broader GHS-R1a expression outside the somatotroph axis.

Molar mass

818.0 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol. 2026;17:1822475. — COMPONENT-LEVEL, NOT blend-level. PubMed-indexed narrative review covering GHRP-2, GHRP-6, sermorelin and other GH secretagogues; discusses the clinical-evidence gap and patient self-administration. Does not study the three-peptide combination as a unit.
• Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. — COMPONENT-LEVEL review covering GHRP-2, GHRP-6, sermorelin combination therapy; cites Sigalos 2017 (below) as its primary human evidence.
• Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. — Anchoring sermorelin-specific review; predates the GHRP combination era, component-level only.
• Sigalos JT, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels. Am J Mens Health. 2017;11(6):1752-1757. — THE ONE BLEND-LEVEL human data point: a retrospective chart review of 105 men prescribed exactly this GHRP-6 + GHRP-2 + sermorelin combination (3x daily SC), 14 of whom met strict inclusion criteria for analysis (mean treatment 134 days; IGF-1 evaluated). NOT a registered/prospective RCT — hence completedHumanRcts stays 0 — but the closest thing to blend-level evidence that exists.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous injection (SC) — also the only route with a blend-level, non-RCT human data point.

Labeled route for sermorelin acetate (pediatric growth-deficiency treatment, per FDA label); SC PK of GHRP-6 in healthy male volunteers; SC infusion of GHRP-2 in healthy men (Laferrère 2005) and graded-dose SC in GH-deficient children; the blend as a three-peptide unit was administered SC 3x daily in the Sigalos 2017 cohort of 105 men (14 analyzed).

Bioavailability: Sermorelin: peak plasma concentrations reached 5-20 min after SC administration of 2 mg to 12 normal volunteers. GHRP-6: bi-exponential SC PK with distribution t1/2 7.6±1.9 min and elimination t1/2 2.5±1.1 h across 1/3/10 μg/kg doses. GHRP-2: SC infusion 1 μg/kg/h for 270 min in healthy men produced a significant GH rise vs saline.

SC is the dominant research and labeled route for all three components, and the only route with a blend-level (though non-RCT) human study. Sermorelin's FDA label specifies SC injection after reconstitution with rotation of injection sites.

Sermorelin: a historical IV bolus formulation (Geref Diagnostic, NDA 19-863, approved Dec 1990) was labeled for diagnostic evaluation of pituitary GH reserve, distinct from the SC daily-dosing GEREF treatment formulation (NDA 20-443); GHRP-6 was characterized in an unregistered Cuban IV dose-escalation safety trial in healthy volunteers; GHRP-2 IV administration is used diagnostically and produces effective GH stimulation.

Bioavailability: Sermorelin's own drug-label adverse-reactions text separately documents reactions 'when administered intravenously for diagnostic use' (flushing, injection-site pain/redness/swelling, nausea, headache, vomiting, dysgeusia, pallor) — confirming IV as a genuinely labeled diagnostic route for the Geref Diagnostic formulation, not an off-label use. GHRP-6 IV dose-escalation (Cuban trial) reported no significant adverse events across escalating doses. GHRP-2 IV administration in short-stature children produced GH peaks ≥20 ng/mL with faster onset than oral dosing.

IV route studied primarily for diagnostic GH stimulation and PK/safety characterization, not chronic use. No IV study of the three-peptide blend as a combined unit exists — this is component-level data.

Intranasal GHRP-2 studied in a clinical trial in children with short stature (Pihoker 1997) and in a 48-week double-blind placebo-controlled trial (Tanaka 2014); intranasal PK comparison of GHRP-2 and GHRP-6 (Johansen 1998). No intranasal data located for sermorelin or for the blend as a unit.

Bioavailability: Intranasal GHRP-2 bioavailability estimated at approximately 50% relative to IV in a comparative PK study; nasal absorption of GHRP-6 was lower than GHRP-2. Intranasal GHRP-2 was well tolerated but produced only a transient GH rise insufficient to change height-SDS vs placebo in GHD children.

Intranasal route studied for GHRP-2 (human) and GHRP-6 (preclinical/animal), component-level only. No intranasal study of sermorelin or of the combined blend.

GHRP-2 tested orally in clinical studies (900 μg/kg b.i.d. for 12 months in GH-deficient children, appetite/weight endpoints); GHRP-6 oral bioavailability approximately 0.3% (animal/preclinical, rapid GI degradation); sermorelin (29-amino-acid peptide) has no human oral PK data confirming adequate plasma levels and is rapidly degraded by GI proteases and DPP-IV.

Bioavailability: GHRP-6 oral bioavailability approximately 0.3% due to rapid GI degradation. GHRP-2 has wider oral bioavailability than GHRP-6 but is still predominantly injected; its oral clinical use targets appetite/weight, not systemic GH-axis therapy. Sermorelin's oral route has no human PK study establishing meaningful systemic exposure.

Oral is not a viable studied route for the blend as a unit; peptide degradation in the GI tract limits absorption for all three components. Oral-stability data do not imply clinically meaningful oral absorption.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $9.78 · median $9.99 · p75 $10.11 · 7 researched vendors

Legit, COA-backed band: $9.00–$11.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$94

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

No independent-lab aggregate purity report specific to the finished three-component blend was located. Component-level only: an independent (Janoshik-verified) Panda Peptides Sermorelin 10mg lot reported 99.213% HPLC purity; research-grade GHRP-2/GHRP-6/Sermorelin materials are typically marketed at ≥95-99% HPLC purity by vendors, unverified at the blend level.

Independent labs cited for this compound

One compound-specific recall located: Pharm D Solutions, LLC (May 23, 2019) recalled all sterile compounded products including two Sermorelin/GHRP-2/GHRP-6 blend lots (3mg/3mg/3mg and 9mg/9mg/9mg lyophilized) for potential lack of sterility assurance; FDA has since terminated this recall. No other recall names the three-component blend.

Buyer red-flag checklist

• GHRP-2 and GHRP-6 are not on the FDA 503A bulks list and are not components of any FDA-approved drug, making compounded blends ineligible for 503A exemptions per two FDA warning letters (United Pharmacy 2019, ImprimisRx 2019).
• FDA classified GHRP-2 (injectable/nasal) and GHRP-6 as Category 2 bulk substances that may present significant safety risks (immunogenicity, aggregation, peptide impurities, reported serious adverse events).
• Sermorelin's only FDA-approved product (Geref) was discontinued commercially in 2008 for non-safety reasons; current supply is compounded/grey-market only.
• A compound-specific sterile-compounding recall (Pharm D Solutions, 2019) included Sermorelin/GHRP-2/GHRP-6 blend lots for potential lack of sterility assurance.
• No single independent lab test (Janoshik/MZ Biolabs/Finnrick) of the finished three-component blend was located; purity claims are component-level only.
• An RUO label is not an importation exemption: unapproved new drugs like these can face FDA border detention under Import Alert 66-41, which authorizes DWPE of unapproved new drugs generally (does not name this blend by name).

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent aggregate (Janoshik/MZ Biolabs/Finnrick) quantifying underdosing/mislabeling prevalence for this specific blend was located. A peptide-industry commentary cites an FDA-adjacent finding that up to 40% of tested online/compounded peptides carried incorrect dosages, but that figure is general to peptides, not specific to this blend, and is reported here only as context, not as a blend-specific rate.

• FDA Import Alert 66-41 authorizes Detention Without Physical Examination (DWPE) of unapproved new drug products promoted in the U.S. via a firm-specific Red List. GHRP-2, GHRP-6, and sermorelin (no FDA-approved product currently marketed) fall within the general scope of unapproved new drugs subject to this alert when imported for human use, though the alert does not name this blend or its components individually.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

The blend itself is not named on the WADA Prohibited List (no product-level schedule exists for a named blend). Per component: sermorelin, GHRP-2, and GHRP-6 are all growth hormone-releasing peptides/factors falling under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times, in- and out-of-competition. USADA confirms sermorelin specifically is prohibited with a Therapeutic Use Exemption highly unlikely to be granted given no approved human therapeutic use.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-selection: positive reports over-represented in 'what worked for you' threads.
• Vendor-affiliated content present (multiple peptide sellers publish blend marketing pages).
• Concomitant TRT and other peptides confound attribution of effects.
• Small, de-identified author mass limits statistical reliability.

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research-use-only three-peptide blend of the GHRH analog Sermorelin with the growth hormone secretagogues GHRP-6 and GHRP-2. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet